Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.